SAVI: molecular mechanisms, clinical spectrum and precision medicine approaches beyond type-I IFN. (PubMed, Front Immunol) - Sep 16, 2026 - "Emerging clinical data indicate that current therapeutic options - including Janus kinase inhibitors (JAKi), biological agents as anifrolumab and solid organ transplantation - for SAVI face limited and often inconsistent long-term efficacy, highlighting a significant unmet need...Finally, we discuss future therapeutic prospects and clinical implications, exploring next-generation frontiers such as patient-derived induced pluripotent stem cell (iPSCs) models, hematopoietic stem cell transplantation (allo-HSCT) and gene editing (GE) technologies. The transition from immune - to a mutational-perspective, provides a foundational framework to optimize diagnostic and therapeutic strategies for precision medicine in SAVI patients."
Journal • Review • Bone Marrow Transplantation • Inflammation • Interferonopathies • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • STING-Associated Vasculopathy with Onset in Infancy • Transplantation • STING
|
|
Chiara Fresia; Enrico Drago; Francesco La Torre; Gabriella Guida; Gerardo Cazzato; Giulia Accorsi; Giuseppe Ingravallo; Jona Papri; Marco Gattorno; Mario Della Mura; Michele Manganelli; Nicole De Lucchi; Paola Cantalice; Roberta Caorsi; Simonetta Simonetti; Stefano Volpi
|